|
Nanobac Pharmaceuticals, Inc. - Sales Analysis Snapshot
Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Nanobac Pharmaceuticals, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.
Nanobac Pharmaceuticals, Inc.. The Group's principal activity is the research and development of therapeutic and diagnostic technologies relating to the pleomorphic pathogen known as nanobacterium sanguineum. The Group is biolifescience company which develops diagnostic tests for the detection of Nanobacterial infection, as well as medications that treat atherosclerosis and coronary heart disease. It has a commercially available serology test for the identification of nanobacterial antibodies and antigens. It also conducts biomedical research and clinical studies in the development of atherosclerosis, gall stones, chronic prostatitis, diabetes, arthritic spurs, cataracts, scleroderma, kidney cysts and kidney stones, certain breast pathology, polycystic kidney disease, solid tumor pathologies, immunosuppressed conditions, dental pulp stone, and neurodegenerative disease. It majorly operates in the United States and Finland.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
